透明质酸在医疗保健中的应用：全球市场

全球透明质酸医疗产品市场预计将从 2025 年的 80 亿美元成长到 2030 年底的 105 亿美元，2025 年至 2030 年的复合年增长率为 5.7%。

北美透明质酸医疗产品市场预计将从 2025 年的 34 亿美元成长到 2030 年底的 41 亿美元，2025 年至 2030 年的复合年增长率为 3.5%。

亚太地区透明质酸医疗产品市场预计将从 2025 年的 17 亿美元成长到 2030 年底的 28 亿美元，2025 年至 2030 年的复合年增长率为 10.1%。

调查范围

本报告概述了全球透明质酸 (HA) 医疗（或保健）产品市场，并分析了当前的市场趋势。本报告涵盖的 HA 医疗产品包括 HA 真皮填充剂、黏弹性补充剂、干眼症治疗眼科黏弹剂(OVD)、用于伤口护理和肌肉骨骼修復的再生产品、粘连屏障以及用于泌尿系统的填充剂。本报告仅涵盖由合格医疗保健专业人员在门诊或外科环境中使用或建议的处方产品。

该报告对 HA 医疗产品市场的估计包括 2024 年基准年的全球收益（百万美元）、2025 年的估计值以及 2025-2030 年的预测数据。报告重点关注关键市场趋势、挑战、机会和供应商格局。报告还涵盖了与市场相关的新产品、收购和合作伙伴关係。报告也分析了环境、社会和企业管治(ESG) 的发展。

竞争格局分析包括每个 HA 医疗产品市场主要企业的市场份额排名，并且还有一个部分介绍主要企业。

报告内容

• 透明质酸（HA）医疗产品全球市场概览
• 全球市场趋势的详细分析，包括 2022 年至 2024 年的历史收益数据、2025 年的估计值以及 2030 年的预测以及预计的复合年增长率
• 透过考虑市场中存在的微观和宏观环境因素以及回顾波特五力模型和行业供应链分析来分析市场机会
• 市场驱动因素、限制因素以及其他影响全球市场的因素的说明
• 涵盖不断发展的技术、当前和未来的市场潜力、研发活动、成长策略、法律规范和报销方案以及市场中的 ESG 趋势
• 透过专有技术、併购和策略倡议，确定最有能力满足这项需求的公司
• 永续性趋势和 ESG 发展概述，重点在于消费者态度、ESG 风险评估和主要企业的实践
• 相关专利分析重点突出已授权和已公布的关键专利
• 全球主要公司简介，包括 AbbVie Inc.、Galderma、Sanofi、Bioventus、IBSA Institut Biochimique SA 和 Fidia Farmaceutici SpA

目录

第一章执行摘要

第二章 市场概况

• 玻尿酸
• 宏观经济因素分析
• 经济成长和收入水平
• 美国关税的影响
• 人口趋势
• 波特五力分析

第三章 市场动态

• 市场动态
• 市场驱动因素
• 扩大透明质酸的临床应用
• 创新和生物技术进步
• 微创手术的趋势
• 市场挑战
• HA高成本且效果短期
• 潜在的不良反应和副作用
• 市场趋势
• 微生物发酵生产玻尿酸
• 玻尿酸混合配方

第四章：监理现状

• 概述
• 美国
• EU
• 日本
• 中国

第五章 新兴技术与发展

• 透明质酸作为药物传递载体
• 3D生物列印
• 基于酵素的透明质酸合成
• 临床试验分析
• 关键要点

第六章市场区隔分析

• 细分市场
• 全球医疗保健领域的透明质酸市场（按产品）
• 真皮填充剂
• 黏稠补充剂
• 眼科产品
• 再生及防沾黏产品
• 泌尿系统填充剂
• 全球透明质酸医疗保健市场（按来源）
• 动物源性玻尿酸
• 微生物发酵
• 地理分布
• 全球医疗保健领域透明质酸市场（按地区）
• 北美洲
• 欧洲
• 亚太地区
• 中东和非洲
• 南美洲

第七章 竞争讯息

• 透明质酸真皮填充剂
• 关键要点
• 市占率分析
• 黏稠补充剂
• 关键要点
• 市占率分析
• 眼科产品
• 再生及防沾黏产品
• 泌尿系统填充剂

第八章 玻尿酸市场的永续性：ESG 视角

• ESG介绍
• 透明质酸市场特有的关键 ESG 议题
• HA 治疗中一次性塑胶对环境的影响
• 大规模微生物透明质酸生产的环境挑战
• 品管在註射透明质酸安全的重要作用
• 结论

第九章 附录

• 调查方法
• 资讯来源
• 简称
• 公司简介
• Abbreviations
• Company Profiles
• ABBVIE INC.
• ANIKA THERAPEUTICS INC.
• BIOVENTUS
• FERRING BV
• FIDIA FARMACEUTICI SPA
• GALDERMA
• IBSA INSTITUT BIOCHIMIQUE SA
• MEDYTOX
• MERZ PHARMA
• NORDIC PHARMA
• SANOFI
• SANTEN PHARMACEUTICAL CO. LTD.
• SEIKAGAKU CORP.
• TEOXANE
• URSAPHARM ARZNEIMITTEL GMBH
• 新兴Start-Ups/市场颠覆者

The global market for hyaluronic acid medical products is estimated to grow from $8 billion in 2025 to $10.5 billion by the end of 2030, at a compound annual growth rate (CAGR) of 5.7% from 2025 to 2030.

The North American market for hyaluronic acid medical products is estimated to grow from $3.4 billion in 2025 to $4.1 billion by the end of 2030, at a CAGR of 3.5% from 2025 to 2030.

The Asia-Pacific market for hyaluronic acid medical products is estimated to grow from $1.7 billion in 2025 to $2.8 billion by the end of 2030, at a CAGR of 10.1% from 2025 to 2030.

Report Scope

This report offers an overview of the global market for hyaluronic acid (HA) medical (or healthcare) products while also analyzing current market trends. The HA medical products covered in this report include HA dermal fillers, viscosupplements, dry eye treatments, ophthalmic viscoelastic devices (OVDs), regenerative products for wound care and musculoskeletal repair, anti-adhesion barriers and bulking agents for urology applications. The report covers only prescription products that may be used or recommended exclusively by qualified healthcare professionals in outpatient settings or during surgical procedures.

The report's estimates of the HA medical products market include global revenue ($ millions) for the base year of 2024, estimates for 2025 and data for the forecast period of 2025 through 2030. The report focuses on the major trends, challenges and opportunities in the market and vendor landscape. It also covers the new products, acquisitions and collaborations related to the market. The report also analyzes environmental, social and corporate governance (ESG) developments.

The report concludes with an analysis of the competitive landscape, which provides a ranking by market share of leading companies in each HA medical product market. There is also a section of profiles of the leading companies.

Report Includes

• An overview of the global market for hyaluronic acid (HA) medical products
• In-depth analysis of global market trends, featuring historical revenue data from 2022-2024, estimated figures for 2025, as well as forecasts for 2030, including projections of compound annual growth rates (CAGRs) through 2030
• Analysis of market opportunities with a review of Porter's Five Forces model and industry supply chain analysis, considering both micro- and macro environmental factors prevailing in the market
• Explanation of market drivers, restraints and other forces impacting the global market
• Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, regulatory framework and reimbursement scenarios, and ESG trends of the market
• Identification of companies best positioned to meet this demand due to their proprietary technologies, mergers and acquisitions, and strategic initiatives
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
• A relevant patent analysis, featuring key granted and published patents
• Profiles of the leading global companies, including AbbVie Inc., Galderma, Sanofi, Bioventus, IBSA Institut Biochimique S.A., and Fidia Farmaceutici S.p.A.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Dynamics
• Emerging Trends
• Analysis by Segment
• Analysis by Region
• Conclusion

Chapter 2 Market Overview

• Hyaluronic Acid
• Analysis of Macroeconomic Factors
• Economic Growth and Income Levels
• Impact of the U.S. Tariffs
• Demographic Trends
• Porter's Five Forces Analysis
• Bargaining Power of Buyers: Moderate to High
• Bargaining Power of Suppliers: Moderate
• Threat of New Entrants: Moderate
• Threat of Substitutes: Moderate to High
• Industry Rivalry: Moderate

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Expanding Clinical Applications of Hyaluronic Acid
• Innovation and Biotechnological Advancements
• Trend Toward Minimally Invasive Procedures
• Market Challenges
• High Cost and Short-Lasting Effects of HA
• Potential Adverse Reactions and Side Effects
• Market Trends
• Microbial Fermentation-based HA Production
• Hybrid Formulations of HA

Chapter 4 Regulatory Landscape

• Overview
• U.S.
• European Union
• Japan
• China

Chapter 5 Emerging Technologies and Developments

• Hyaluronic Acid as a Drug Delivery Vehicle
• Three-Dimensional Bioprinting
• Enzyme-based Hyaluronic Acid Synthesis
• Clinical Trial Analysis
• Key Takeaways

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Global Market for Hyaluronic Acid in Healthcare, by Product
• Dermal Fillers
• Viscosupplements
• Ophthalmic Products
• Regenerative and Anti-Adhesion Products
• Bulking Agents for Urology Applications
• Global Market for Hyaluronic Acid in Healthcare, by Source
• Animal-derived HA
• Microbial Fermentation
• Geographic Breakdown
• Global Market for Hyaluronic Acid in Healthcare, by Region
• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America

Chapter 7 Competitive Intelligence

• Hyaluronic Acid Dermal Fillers
• Key Takeaways
• Market Share Analysis
• Viscosupplements
• Key Takeaways
• Market Share Analysis
• Ophthalmic Products
• Regenerative and Anti-Adhesion Products
• Bulking Agents for Urology Applications

Chapter 8 Sustainability in Hyaluronic Acid Market: An ESG Perspective

• Introduction to ESG
• Key ESG Issues Specific to Hyaluronic Acid Market
• Environmental Impact of Single-Use Plastics in HA-based Treatments
• Environmental Challenges of Large-Scale Microbial HA Production
• Critical Role of Quality Control in Injectable HA Safety
• Concluding Remarks

Chapter 9 Appendix

• Methodology
• Information Sources
• Abbreviations
• Company Profiles
• ABBVIE INC.
• ANIKA THERAPEUTICS INC.
• BIOVENTUS
• FERRING B.V.
• FIDIA FARMACEUTICI S.P.A.
• GALDERMA
• IBSA INSTITUT BIOCHIMIQUE SA
• MEDYTOX
• MERZ PHARMA
• NORDIC PHARMA
• SANOFI
• SANTEN PHARMACEUTICAL CO. LTD.
• SEIKAGAKU CORP.
• TEOXANE
• URSAPHARM ARZNEIMITTEL GMBH
• Emerging Start-ups/Market Disruptors

List of Tables

• Summary Table : Global Market for Hyaluronic Acid Medical Products, by Region, Through 2030
• Table 1 : Global Market for Hyaluronic Acid Medical Products, by Product, Through 2030
• Table 2 : Global Nonsurgical Procedures Performed by Plastic Surgeons, 2022 versus 2023
• Table 3 : Global Minimally Invasive Cosmetic Procedures, 2024 versus 2023
• Table 4 : Commercially Available Hyaluronic Acid Dermal Fillers
• Table 5 : Global Market for Dermal Fillers, by Region, Through 2030
• Table 6 : Global Market for Viscosupplements, by Region, Through 2030
• Table 7 : Commercially Available Three-Injection Regimen Viscosupplements
• Table 8 : Commercially Available Single-Injection Regimen HA Viscosupplements
• Table 9 : Commercially Available Five-Injection Regimen HA Viscosupplements
• Table 10 : Global Market for Viscosupplements, by Regimen Type, Through 2030
• Table 11 : Global Market for Ophthalmic Products, by Region, Through 2030
• Table 12 : Global Market for Ophthalmic Products, by Type, Through 2030
• Table 13 : Commercially Available Ophthalmic Viscosurgical Devices (OVDs)
• Table 14 : Commercially Available Prescription Regenerative Solutions
• Table 15 : Commercially Available Prescription Anti-Adhesion Products
• Table 16 : Global Market for Regenerative and Anti-Adhesion Products, by Region, Through 2030
• Table 17 : Commercially Available HA-Based Bulking Agents for Urology Applications
• Table 18 : Global Market for Bulking Agents for Urology Applications, by Region, Through 2030
• Table 19 : Medical Products Made of Animal-derived HA, 1997-2019
• Table 20 : Global Market for Hyaluronic Acid Medical Products, by Hyaluronic Acid Source, Through 2030
• Table 21 : Global Market for Hyaluronic Acid Medical Products, by Region, Through 2030
• Table 22 : North American Market for Hyaluronic Acid Medical Products, by Product, Through 2030
• Table 23 : North American Market for Hyaluronic Acid Medical Products, by Country, Through 2030
• Table 24 : HA Injectable Aesthetic Procedures Performed, by Country, 2023
• Table 25 : European Market for Hyaluronic Acid Medical Products, by Product, Through 2030
• Table 26 : European Market for Hyaluronic Acid Medical Products, by Country, Through 2030
• Table 27 : Asia-Pacific Market for Hyaluronic Acid Medical Products, by Product, Through 2030
• Table 28 : Asia-Pacific Market for Hyaluronic Acid Medical Products, by Country, Through 2030
• Table 29 : MEA Market for Hyaluronic Acid Medical Products, by Product, Through 2030
• Table 30 : South American Market for Hyaluronic Acid Medical Products, by Product, Through 2030
• Table 31 : Information Sources for this Report
• Table 32 : Abbreviations Used in This Report
• Table 33 : AbbVie Inc.: Company Snapshot
• Table 34 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
• Table 35 : AbbVie Inc.: Product Portfolio
• Table 36 : AbbVie Inc.: News/Key Developments, 2023 and 2024
• Table 37 : Anika Therapeutics Inc.: Company Snapshot
• Table 38 : Anika Therapeutics Inc.: Financial Performance, FY 2023 and 2024
• Table 39 : Anika Therapeutics Inc.: Product Portfolio
• Table 40 : Anika Therapeutics Inc.: News/Key Developments, 2023 and 2024
• Table 41 : Bioventus: Company Snapshot
• Table 42 : Bioventus: Financial Performance, FY 2023 and 2024
• Table 43 : Bioventus: Product Portfolio
• Table 44 : Bioventus: News/Key Developments, 2023
• Table 45 : Ferring B.V.: Company Snapshot
• Table 46 : Ferring B.V.: Financial Performance, FY 2023 and 2024
• Table 47 : Ferring B.V.: Product Portfolio
• Table 48 : Fidia Farmaceutici S.p.A.: Company Snapshot
• Table 49 : Fidia Farmaceutici S.p.A.: Financial Performance, FY 2023 and 2024
• Table 50 : Fidia Farmaceutici S.p.A.: Product Portfolio
• Table 51 : Fidia Farmaceutici S.p.A.: News/Key Developments, 2023 and 2024
• Table 52 : Galderma: Company Snapshot
• Table 53 : Galderma: Financial Performance, FY 2023 and 2024
• Table 54 : Galderma: Product Portfolio
• Table 55 : Galderma: News/Key Developments, 2023 and 2024
• Table 56 : IBSA Institut Biochimique SA: Company Snapshot
• Table 57 : IBSA Institut Biochimique SA: Product Portfolio
• Table 58 : IBSA Institut Biochimique SA: News/Key Developments, 2024
• Table 59 : Medytox: Company Snapshot
• Table 60 : Medytox: Financial Performance, FY 2023 and 2024
• Table 61 : Medytox: Product Portfolio
• Table 62 : Merz Pharma: Company Snapshot
• Table 63 : Merz Pharma: Product Portfolio
• Table 64 : Nordic Pharma: Company Snapshot
• Table 65 : Nordic Pharma: Product Portfolio
• Table 66 : Nordic Pharma: News/Key Developments, 2023-2025
• Table 67 : Sanofi: Company Snapshot
• Table 68 : Sanofi: Financial Performance, FY 2023 and 2024
• Table 69 : Sanofi: Product Portfolio
• Table 70 : Santen Pharmaceutical Co. Ltd.: Company Snapshot
• Table 71 : Santen Pharmaceutical Co. Ltd.: Financial Performance, FY 2023 and 2024
• Table 72 : Santen Pharmaceutical Co. Ltd.: Product Portfolio
• Table 73 : Seikagaku Corp.: Company Snapshot
• Table 74 : Seikagaku Corp.: Financial Performance, FY 2023 and 2024
• Table 75 : Seikagaku Corp.: Product Portfolio
• Table 76 : Seikagaku Corp.: News/Key Developments, 2024 and 2025
• Table 77 : Teoxane: Company Snapshot
• Table 78 : Teoxane: Product Portfolio
• Table 79 : URSAPHARM Arzneimittel GmbH: Company Snapshot
• Table 80 : URSAPHARM Arzneimittel GmbH: Product Portfolio
• Table 81 : List of a Few Emerging Startups/Market Disruptors

List of Figures

• Summary Figure : Global Market Shares of Hyaluronic Acid Medical Products, by Region, 2024
• Figure 1 : Key Properties of Hyaluronic Acid
• Figure 2 : Porter's Five Forces Analysis - Hyaluronic Acid in Healthcare Market
• Figure 3 : Market Dynamics for Hyaluronic Acid in Healthcare
• Figure 4 : Active Clinical Trials for Hyaluronic Acid, by Indication Type, 2025
• Figure 5 : Global Market Shares of Hyaluronic Acid Medical Products, by Product, 2024
• Figure 6 : Global Market Shares of Viscosupplements, by Regimen Type, 2024
• Figure 7 : Global Market Shares of Ophthalmic Products, by Type, 2024
• Figure 8 : Global Market Shares of Hyaluronic Acid Medical Products, by Hyaluronic Acid Source, 2024
• Figure 9 : Global Market Shares of Hyaluronic Acid Medical Products, by Region, 2024
• Figure 10 : North American Market Shares of Hyaluronic Acid Medical Products, by Product, 2024
• Figure 11 : North American Market Shares of Hyaluronic Acid Medical Products, by Country, 2024
• Figure 12 : European Market Shares of Hyaluronic Acid Medical Products, by Product, 2024
• Figure 13 : European Market Shares of Hyaluronic Acid Medical Products, by Country, 2024
• Figure 14 : Asia-Pacific Market Shares of Hyaluronic Acid Medical Products, by Product, 2024
• Figure 15 : Asia-Pacific Market Shares of Hyaluronic Acid Medical Products, by Country, 2024
• Figure 16 : MEA Market Shares of Hyaluronic Acid Medical Products, by Product, 2024
• Figure 17 : South American Market Shares of Hyaluronic Acid Medical Products, by Product, 2024
• Figure 18 : Global Market Shares of Hyaluronic Acid Dermal Fillers, by Company, 2024
• Figure 19 : Global Market Shares of Viscosupplements, by Company, 2024
• Figure 20 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 21 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 22 : Anika Therapeutics Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 23 : Anika Therapeutics Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 24 : Bioventus: Revenue Share, by Business Unit, FY 2024
• Figure 25 : Bioventus: Revenue Share, by Country/Region, FY 2024
• Figure 26 : Ferring B.V.: Revenue Share, by Business Unit, FY 2024
• Figure 27 : Ferring B.V.: Revenue Share, by Country/Region, FY 2024
• Figure 28 : Fidia Farmaceutici S.p.A.: Revenue Share, by Business Unit, FY 2024
• Figure 29 : Fidia Farmaceutici S.p.A.: Revenue Share, by Country/Region, FY 2024
• Figure 30 : Galderma: Revenue Share, by Business Unit, FY 2024
• Figure 31 : Galderma: Revenue Share, by Country/Region, FY 2024
• Figure 32 : Medytox: Revenue Share, by Business Unit, FY 2024
• Figure 33 : Medytox: Revenue Share, by Country/Region, FY 2024
• Figure 34 : Sanofi: Revenue Share, by Business Unit, FY 2024
• Figure 35 : Sanofi: Revenue Share, by Country/Region, FY 2024
• Figure 36 : Santen Pharmaceutical Co. Ltd.: Revenue Share, by Business Unit, FY 2024
• Figure 37 : Santen Pharmaceutical Co. Ltd.: Revenue Share, by Country/Region, FY 2024
• Figure 38 : Seikagaku Corp.: Revenue Share, by Business Unit, FY 2024
• Figure 39 : Seikagaku Corp.: Revenue Share, by Country/Region, FY 2024